Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Aytu Biopharma (AYTU) over the last 16 years, with Sep 2025 value amounting to $125.0 million.

  • Aytu Biopharma's Liabilities and Shareholders Equity rose 7.91% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.6 million, marking a year-over-year decrease of 0.90%. This contributed to the annual value of $124.2 million for FY2025, which is 5.15% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Liabilities and Shareholders Equity is $125.0 million, which was up 0.65% from $124.2 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Liabilities and Shareholders Equity peaked at $271.6 million during Q1 2021, and registered a low of $115.8 million during Q3 2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $125.0 million (2025), whereas its average is $127.3 million.
  • In the last 5 years, Aytu Biopharma's Liabilities and Shareholders Equity surged by 73.31% in 2021 and then crashed by 48.20% in 2022.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Liabilities and Shareholders Equity stood at $223.8 million in 2021, then slumped by 36.81% to $141.4 million in 2022, then decreased by 7.20% to $131.2 million in 2023, then dropped by 11.45% to $116.2 million in 2024, then increased by 7.91% to $125.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $125.0 million in Q3 2025, compared to $124.2 million in Q2 2025 and $124.2 million in Q1 2025.